Scientists are testing an entirely new way to fight heart disease: whether gene editing might offer a one-time fix for high ...

Monounsaturated and polyunsaturated fats can help lower LDL cholesterol and raise HDL cholesterol. Heart-healthy options ...

“Bad,” or LDL, cholesterol is a major risk factor for heart disease and most people are screened for it as part of their yearly physicals ...

If you are concerned about your risk of developing cardiovascular disease, you’ll usually get a specific blood test to look at your cholesterol levels to see where things stand. At least, that’s how ...

To get a picture of how much cholesterol you have circulating in your system that could deposit on your blood vessel walls and raise the risk for a heart attack or other event, blood tests are done to ...

This article was reviewed by Felix Gussone, MD. Key Takeaways: Preparing properly for lab tests helps ensure your results are accurate and reliable. Some tests — ...

They’re getting to the heart of the issue. Doctors say a simple “three-pronged” blood test can accurately predict a patient’s risk of heart attack and stroke 30 years ahead of time. At present, medics ...

What Is a Lipid Profile? Lipid profile, or sometimes referred to as lipid panel, is a blood test that's used as a screening tool for abnormalities in lipids, such as cholesterol and triglycerides. It ...

What if a blood test could reveal that your child is at high risk for early heart disease years in the future, giving you a chance to prevent it now? A big study in England did that – screening ...

While 86 million adults in the United States have high cholesterol levels, one-third of Americans say they haven’t had their numbers checked in the past five years. Getting your cholesterol tested — ...

In the intricate symphony of your body’s functions, cholesterol plays a crucial role. This waxy substance, essential for building cells and producing hormones, hums along quietly in the background — ...

NewAmsterdam Pharma’s drug reduced cholesterol in patients with a genetic disorder by 41% at Week 52, confirming the therapy’s efficacy but falling outside of the range shown in a previous study. The ...